Answers are grounded in this paper and cite their sources.
Randomized animal study demonstrates that SMP24-AgCuO nanocarriers suppress tumor inflammation via EGFR/p38 pathways in mice, highlighting a novel targeted anticancer strategy.
Background and aim Chronic inflammation plays a critical role in tumor progression through dysregulated cytokine networks and key signaling mediators such as p38-MAPK and epidermal growth factor receptor (EGFR). This study aimed to investigate the anti-inflammatory and anticancer efficacy of the scorpion venom peptide Smp24 (SMP24) and its bimetallic nano-conjugates, SMP24-ZnOCuO, and SMP24-AgCuO, in a murine model of solid Ehrlich carcinoma (SEC).Experimental approach Solid tumors were induced in female Swiss albino mice via subcutaneous injection of 2.5 × 106 Ehrlich carcinoma cells. After tumor establishment (∼50 mm³), mice were randomly assigned to nine groups (n = 6/group), including controls, treatment groups, and a cisplatin reference group. Treatments were administered intraperitoneally every 48 hrs for 2 weeks. At the end of the experiment, blood, tumor tissues, and organs were collected for biochemical, cytokine, molecular, histopathological, and immunohistochemical analyses.Key findings SEC-bearing mice showed significant increases in body weight, organ indices, liver enzymes, and creatinine levels, alongside elevated pro-inflammatory cytokines (IL-6, IL-8) and reduced anti-inflammatory cytokines (IL-4, IL-10). Histopathological alterations and increased expression of p38 and EGFR were also observed. Treatment with SMP24 and its nano-conjugates significantly restored cytokine balance, reduced organ toxicity markers, and improved tissue architecture. Notably, SMP24-AgCuO demonstrated superior efficacy, markedly suppressing IL-6 and IL-8, enhancing IL-4 and IL-10, and significantly downregulating p38 and EGFR expression compared to cisplatin.Conclusions SMP24-conjugated bimetallic nanocarriers, particularly SMP24-AgCuO, exhibit potent anti-inflammatory and anticancer effects through modulation of the EGFR/p38-MAPK signaling axis. These findings highlight their potential as a targeted and safer therapeutic strategy for managing tumor-associated inflammation and cancer progression.
No takes yet. Share an insight, caveat, or question.
Ghodeif et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: